Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Canagliflozin31 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | 2021 | Details |
| A02788 | 34239714 | Oman Med J | Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. | 2021 | Details |
| A03455 | 33994437 | Intern Med | Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A03789 | 33862461 | Biochem Biophys Res Commun | Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. | 2021 | Details |
| A04950 | 33439540 | J Gastroenterol Hepatol | The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. | 2020 | Details |
| A05042 | 33396949 | Metabolites | Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. | 2020 | Details |
| A07543 | 32448832 | Intern Med | SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. | 2020 | Details |
| A08104 | 32245205 | Int J Mol Sci | Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. | 2020 | Details |
| A08703 | 32017594 | Am J Physiol Endocrinol Metab | Combined effect of canagliflozin and exercise training on high-fat diet-fed mice. | 2020 | Details |
| A08737 | 32006266 | Adv Exp Med Biol | Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. | 2021 | Details |
| A09583 | 31686884 | Diabetes Metab Syndr Obes | Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. | 2019 | Details |
| A09671 | 31652578 | Int J Mol Sci | The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. | 2019 | Details |
| A10470 | 31324087 | J Assoc Physicians India | Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A11204 | 31000862 | J Pak Med Assoc | Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. | 2019 | Details |
| A11215 | 30993553 | Clin Drug Investig | Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2019 | Details |
| A12164 | 30577089 | Hepatol Res | Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. | 2019 | Details |
| A12190 | 30568471 | Diabetes Metab Syndr Obes | Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. | 2018 | Details |
| A12420 | 30461221 | J Diabetes Investig | Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. | 2019 | Details |
| A12457 | 30447037 | Diabetes Obes Metab | Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. | 2018 | Details |
| A12665 | 30338118 | Obes Sci Pract | Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13517 | 29935547 | J Pharm Pharm Sci | Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. | 2018 | Details |
| A14053 | 29608898 | Eur J Pharmacol | Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. | 2018 | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | 2018 | Details |
| A14455 | 29402900 | Sci Rep | Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. | 2018 | Details |
| A19328 | 26628836 | J Clin Exp Hepatol | Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015 | Details |
| A44116 | 29702499 | Curr Opin Cardiol | New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. | 2018 | Details |
| A49443 | 35748073 | Yonsei Med J | Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy. | 2022 | Details |
| A49867 | 35614469 | Cardiovasc Diabetol | The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. | 2022 | Details |
| A49933 | 35589613 | Diabetes Obes Metab | Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. | 2022 | Details |
| A49962 | 35581956 | Hepatol Commun | Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. | 2022 | Details |